Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Reimbursement for targeted therapy: a challenge for community practitioners

Stefanie Zschaebitz • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer

Stefanie Zschaebitz, Heidelberg University Hospital, Heidelberg, Germany, emphasizes the importance of reimbursement and accessibility for circulating tumor cells (CTCs) and cell-free DNA (cfDNA) testing, particularly for community practitioners, highlighting that ease of sample collection and submission is crucial for widespread adoption. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stefanie Zschaebitz

The importance of reimbursement and accessibility for CTCs and cfDNA testing
0:26
The importance of reimbursement and accessibility for CTCs and cfDNA testing
Stefanie Zschaebitz • 1 Jun 2025
The use of ctDNA in prostate cancer diagnosis and treatment
0:42
The use of ctDNA in prostate cancer diagnosis and treatment
Stefanie Zschaebitz • 2 Jun 2025
Integrating genomic biomarkers into prostate cancer treatment selection
0:53
Integrating genomic biomarkers into prostate cancer treatment selection
Stefanie Zschaebitz • 2 Jun 2025
Enhancing our understanding of HRR gene defects in prostate cancer
0:37
Enhancing our understanding of HRR gene defects in prostate cancer
Stefanie Zschaebitz • 2 Jun 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals